导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.55% | 1370/4773 |
| 近一周 | -2.51% | 2409/5462 |
| 近一月 | -4.94% | 2882/5421 |
| 近一季 | -8.52% | 2833/5209 |
| 近半年 | -5.73% | 2937/4920 |
| 近一年 | 9.15% | 1119/4366 |
| 近两年 | 72.89% | 922/2954 |
| 近三年 | 38.68% | 753/2253 |
| 成立以来 | 93.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.98% 1112/4961 |
18.98% 1334/5312 |
- - |
- - |
| 2025 | 31.94% 1205/4813 |
2.22% 1434/3635 |
2.05% 1915/4076 |
24.51% 1458/4524 |
1.58% 1315/4813 |
| 2024 | 6.25% 1777/3463 |
-2.94% 1456/2808 |
-5.01% 1618/3014 |
15.72% 1644/3129 |
-0.42% 1420/3463 |
| 2023 | -5.11% 716/2656 |
7.66% 538/2280 |
-3.76% 890/2385 |
-4.31% 1111/2515 |
-4.29% 952/2655 |
| 2022 | -16.84% 519/2207 |
-13.20% 715/1919 |
3.85% 1083/2016 |
-10.22% 364/2113 |
2.75% 845/2208 |
| 2021 | 19.46% 192/1822 |
-1.01% 418/1255 |
10.35% 470/1330 |
5.46% 272/1466 |
3.71% 400/1822 |
| 2020 | 28.23% 565/1250 |
-2.98% 283/1028 |
17.18% 388/1067 |
8.34% 722/1164 |
4.10% 868/1184 |
| 2019 | - - |
- - |
-3.32% 388/804 |
0.60% 504/850 |
6.70% 570/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证500ETF联接发起式C VS. 长安沪深300非周期A(740101) |